New
12-month
Phase 1/2
interim results

34%

mean IOP reduction1*

*

In the 78-mcg arm; similar results were seen in the 39-mcg arm.

98%

of patients drop-free1†

†

In the 78-mcg arm; similar results were seen in the 39-mcg arm.

100%

of eyes achieved BCDVA ≥20/321‡

‡

Across all arms.

Cathleen
McCabe, MD, on
the BIM-IOL System

See the video

Reference: 1. SpyGlass Pharma. Data on file.